title: Recombinant human lipocalin 2 acts as an antibacterial agent to prevent platelet contamination.
abstract: BACKGROUND
  Bacterial contamination of platelet products is the major infectious risk in blood transfusion medicine, which can result in life-threatening sepsis in recipient. Lipocalin 2 (Lcn2) is an iron-sequestering protein in the antibacterial innate immune response, which inhibit bacterial growth. This study was aimed to evaluate the antibacterial property of Lcn2 in preventing bacterial contamination of platelets.
  
  
  METHODS
  Recombinant Lcn2 was expressed in a eukaryotic expression system and following purification and characterization of the recombinant Lcn2, its minimum inhibitory concentration was determined. Then, platelet concentrates were inoculated with various concentrations of Staphylococcus epidermidis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and Enterococcus faecalis, and the antibacterial effects of Lcn2 was evaluated at 20-24 °C.
  
  
  RESULTS
  Results revealed that Lcn2 effectively inhibited the growth of 1.5 × 10(4) CFU/ml S. epidermidis, P. aeruginosa, K. pneumoniae, E. coli, and E. faecalis at 40 ng/ml. At this concentration, Lcn2 also inhibited the growth of 1.5 × 10(3) CFU/ml Staphylococcus aureus and Proteus mirabilis.
  
  
  CONCLUSIONS
  Recombinant Lcn2 inhibited growth of a variety of platelet-contaminating bacteria. Therefore, supplementation of platelet concentrates with Lcn2 may reduce bacterial contamination.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Bakhshandeh
authors.forename: Raheleh
authors.initials: R
authors.lastname: Halabian
authors.forename: Abbas Ali
authors.initials: AA
authors.lastname: Imani Fooladi
authors.forename: Ali
authors.initials: A
authors.lastname: Jahanian-Najafabadi
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Jalili
authors.forename: Mehryar Habibi
authors.initials: MH
authors.lastname: Roudkenar
mesh_terms: D000209:Acute-Phase Proteins / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000382:microbiology*; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins / Q000494:pharmacology*; D017713:Platelet Transfusion / Q000009:adverse effects / Q000379:methods*; D011518:Proto-Oncogene Proteins / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013212:Staphylococcus epidermidis / Q000187:drug effects
chemical_list: D000209:Acute-Phase Proteins; D000900:Anti-Bacterial Agents; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins
keywords: Bacterial infections; Lcn2/NGAL; Platelet; Recombinant